Persistent, echocardiography-assessed right ventricle dysfunction (RVD) and/or pulmonary hypertension (PHT) are relatively frequent findings after an acute pulmonary embolism (PE). It has been suggested that echocardiography might predict long-term adverse events. Our objectives were to evaluate the prognostic value of RVD or isolated PHT 6 months after an acute PE with regard to all-cause mortality or venous thromboembolism (VTE) recurrence.
Introduction
Echocardiography-assessed right ventricle dysfunction (RVD) and pulmonary hypertension (PHT) are frequent findings in patients with acute pulmonary embolism (PE), even in those cases with normal blood pressure on admission. 1 There are several studies that demonstrate that RVD and/or PHT persist after the acute phase of PE in a significant proportion of cases. 2, 3 RVD might predict adverse outcomes in the short-term, but very few studies have evaluated the long-term consequences of persistent right ventricular pressure overload. 4, 5 The aim of the present study was to assess the prognostic value of echocardiographic findings 6 months after an acute PE, with regard to long-term clinical outcome. The primary endpoints of the study were all-cause mortality and venous thromboembolism (VTE) recurrence.
Methods
From April 2005 to August 2008, consecutive, haemodynamically stable patients presenting to our hospital with PE were prospectively recruited for a study aimed to assess the prevalence and 6-month evolution of echocardiography-detected RVD and PHT. 6 Inclusion criteria were: age .18 years and confirmed PE by computed tomography pulmonary angiography (CTPA). Exclusion criteria were: massive PE (defined as the presence of two consecutive systolic blood pressure measurements ,90 mmHg measured .15 min apart); comorbidity causing the patient's physician to predict a 6-month mortality .50% (e.g. metastatic cancer, end-stage respiratory disease or heart failure); creatinine clearance level ,35 mL/min or a history of allergy to iodinated contrast media. Prior VTE was not an exclusion criterion in the first study. The study protocol and results have been reported elsewhere. 6 Briefly, we found that right ventricular pressure overload was a frequent finding at diagnosis in haemodynamically stable PE patients, and it persisted in a significant proportion of cases 6 months after the diagnosis; RVD and isolated PHT were found at diagnosis in 25 (24.5%) and 20 (19.6%) cases, respectively (22 of the patients with RVD had also PHT). At the 6-month follow-up visit, 8 (7.9%) patients had RVD and other 12 (11.8%) had isolated PHT (PHT was found in 7 of the 8 cases with RVD). We found that residual vascular obstruction in CTPA correlated with the persistence of echocardiograhic abnormalities. Neither RVD nor PHT were significantly associated with adverse outcome events.
In the present study, we assessed the vital status and the incidence of PE-related adverse events in the patients included in the original study. We obtained information about the present vital status, hospital admissions, treatments, primary care physician visits, and emergencyroom visits from a centralized clinical data management programme. When information about the vital status was not available through this Programme, we tried to contact directly with the patient or relatives. The cause of death and diagnosis of adverse events were obtained from medical reports. When medical reports were not available, efforts was made to collect information concerning the cause of death. The present, non-interventional study was approved by our institution's review board.
Echocardiography
Echocardiographic examinations were performed at diagnosis and at the 6-month follow-up visit, as previously described, 6 using a SONOS 5500 (Hewlett Packard, Palo Alto, CA, USA) ultrasound imaging system with a S4 transducer. For the purpose of this study, videotapes of the echocardiograms were read by a single, highly experienced echocardiographer, who was blinded to the patients' clinical status. In all cases, M-mode, two-dimensional, Doppler (continuous and pulsed wave), and colour Doppler were performed with the patient in the left lateral position. The structure of the mitral, aortic, tricuspid, and pulmonary valves (different grades of regurgitation and stenosis were assessed), and the systolic and diastolic function of the left ventricle (LV) were systematically assessed. We assessed whether patients had either RVD or isolated PHT. PHT was defined as pulmonary arterial systolic pressure (PASP) . 40 mmHg. 2, 7 PASP was derived from the right atrioventricular pressure gradient using peak velocity of tricuspid flow regurgitation with continuous wave Doppler in the apical four chamber view and the modified Bernoulli equation. 8 Right atrial pressure was considered equal to 5 or 10 mmHg according to whether or not the inferior vena cava collapsed during inspiration, respectively. 9 Individuals with at least one of the following findings were diagnosed as having RVD: Right ventricle hypokinesis (asymmetrical or delayed contraction), paradoxical septal systolic motion or right ventricular dilatation (end-diastolic diameter .30 mm or right to left ventricular end-diastolic diameter ratio ≥1 in apical four-chamber view); RV systolic function was assessed using tricuspid annular plane systolic excursion (TAPSE). TAPSE was calculated as the index of right ventricular global systolic function by the difference between end-diastolic and end-systolic measurements (in millimetres). Patients were considered to have abnormal RV systolic function if they had reduced values of TAPSE (,15 mm).
Computed tomographic pulmonary angiography
All CTPA were performed within 6 h of patient admission to the hospital and repeated after 6 month as previously described. 6 One hundred millilitres of non-ionic contrast was administered intravenously at an injection rate of 2. ). An imaging delay of 20 s was used, and overlapping images were reconstructed every 1.5 mm and viewed on films at lung and mediastinal settings. PE was diagnosed by the on-duty radiologist if an intraluminal filling defect was seen. For the purpose of the study, the images were reviewed by an experienced senior radiologist who was blinded to the patients' clinical status and echocardiography data.
Management strategies
All the patients included in the original study were treated with anticoagulation, as previously described, and thrombolytic treatment was not used in any case. 6 After the 6-month visit, the duration of anticoagulation was decided by the attending physician according to standard clinical criteria. Continuation of anticoagulation therapy was recommended regardless of the 6-month echocardiography findings. After hospital discharge, patients were educated about the signs and symptoms of recurrent VTE and instructed to return to the hospital if they noted any.
Definition of study endpoints
The primary study outcomes were all-cause mortality and VTE recurrence. The criterion for diagnosis of recurrence of PE was a new filling defect in CTPA. The criteria for diagnosis of deep vein thrombosis (DVT) as a recurrence of VTE in patients without DVT at baseline were the presence of a non-compressible proximal vein on ultrasonography or an intraluminal filling defect on venography. In cases with DVT at baseline, criteria for recurrence of DVT were abnormal results on ultrasonography or venography in a different venous segment, an extension of a previous intraluminal filling on venography, or a 4-mm or greater increase in thrombus diameter on ultrasonography.
Statistical analysis
Data are expressed as mean + SD or as percentages. The D'Agostino-Pearson test was used to assess the normal distribution of data. For continuous variables, comparisons between groups were made using unpaired t-test or Mann-Whitney rank-sum test, as appropriate. Fisher's exact test was employed for categorical variables. We used univariate and multivariate Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for different variables. Multivariate analyses were performed using a stepwise forward regression model in which each variable with P , 0.1 or less on univariate analysis was entered into the model. P-values are two-sided and P , 0.05 was considered statistically significant.
Long-term clinical outcome of patients with persistent right ventricle dysfunction or pulmonary hypertension
Results

Patients and management
One hundred and ten patients (mean age: 69 + 15 years) were considered for inclusion in the original study, as previously described. One hundred and one completed the protocol, including the 6-month visit follow-up. Table 1 summarizes right ventricular echocardiographic parameters, both at the time of the diagnosis of PE and at the 6-month visit. Figure 1 shows the flow diagram for the present study. Time from the inclusion on the original study until the last contact was 2.81 + 1.06 years. Information on the evolution of six patients could not be obtained. Thus, 95 patients completed the present study. Seventeen (17.9%) of these patients were treated with long-term anticoagulation. The reasons for extending anticoagulation beyond 6 months were: diagnosis of atrial fibrillation (six cases), inferior vena cava filter placement (one patient), diagnosis of other procoagulant conditions (four patients), and the fact that the PE embolism at the inclusion in the original study was an episode of recurrent VTE (six cases).
The percentages of patients who were anticoagulated on the longterm were not significantly different in patients with or without RVD/PHT (23.5 vs. 16.6%, respectively; P ¼ 0.49).
Long-term incidence of adverse effects Figure 1 shows the long-term outcomes of the patients included in the study. Seventeen patients (17.8%) had RVD or PHT 6 months after PE. Table 2 compares the characteristics of patients categorized according to 6-month echocardiography findings. There were no significant differences between both groups, except that dyspnoea was more frequently reported among patients with persistent right ventricular pressure overload. Differences in age between both groups approached statistical significance. Two patients died and three suffered VTE recurrence in the group of cases with RVD or PHT. Seventy-eight patients (82.1%) had a normal echocardiography 6 months after PE. There were seven deaths and nine VTE recurrences in this group. We were unable to obtain accurate information regarding the cause of death in four patients. None of the other deaths were attributed to PE; two patients died from sepsis, one from pneumonia, one from terminal idiopathic pulmonary fibrosis, and another one from terminal cancer. All of the VTE recurrences happened in patients who were not under anticoagulation therapy. Table 3 compares the characteristics of patients who died with those who survived. Patients who died were significantly older, but there were no more significant differences between both groups. A multivariate analysis stratified by maintenance of anticoagulant treatment (Table 4) showed that age was the only independent factor for all-cause mortality. No clinical variable was associated with recurrent VTE (Table 5) . We repeated the analysis excluding those patients who had known comorbidity (e.g. pulmonary fibrosis, chronic obstructive pulmonary disease) that might account for right ventricular overload, with similar results (data not shown).
Discussion
The present study has not found an association between persistent echocardiographic signs of right ventricular pressure overload (RVD and PHT) 6 months after an episode of haemodynamically stable PE and adverse events (all-cause mortality or VTE recurrence). RVD and PHT are relatively frequent findings after PE, even in cases that present without haemodynamic instability. 1 The echocardiographic abnormalities persist 6 months to 1 year after the acute PE event in a significant proportion of patients. 2 -4,6 The short-term prognostic significance of echocardiography-detected RVD in haemodynamically stable PE is under debate, although most studies suggest that these patients are at a higher risk of suffering adverse outcome events. 1,10,11 Therefore, the main role of echocardiography in non-high risk (i.e. haemodynamically stable) PE is further prognostic stratification to the low-or intermediate-risk categories. 12 The long-term prognostic value of persistent RVD or PHT is even less clear, and current guidelines on the management of PE do not make clear recommendations on the role and indication of follow-up echocardiograhy. 12 Echocardiography beyond the acute setting is used mainly to detect chronic thromboembolic PHT (CTPH) when there is a clinical suspicion of this disease. Some studies suggest that a subset of patients with a severe thromboembolic episode might constitute a high-risk group for the development of CTPH and should be subjected to strict follow-up with echocardiography. 13 Although CTPH is a serious disease that carries out a bad prognosis, it is not clear if the persistence of right ventricular pressure overload in the early months after an episode of PE has clinical consequences. There is a paucity of data in the medical literature concerning this question. To the best of our knowledge, only two studies have previously addressed this issue. Ribeiro et al.
performed echocardiography in 78 patients with PE at the time of diagnosis and repeatedly during the year following the acute event and carried out a 5-year survival analysis, which found that none of the deaths was attributed to PE. 4 They concluded that diagnosis of cancer, age and a PASP . 35 mmHg at 1-month follow-up were significantly associated with a higher mortality rate at the end of the 5-year observation period. 4 Grifoni et al. Results are expressed as mean + SD or as number (percentages) of cases. RVD, right ventricle dysfunction; PHT, pulmonary hypertension; PE, pulmonary embolism; VTE, venous thromboembolism.
discharge in 301 consecutive patients with PE. The finding of PHT was included among the diagnostic criteria for RVD. They observed that persistent RVD at hospital discharge was associated with recurrent VTE and PE-related mortality. They suggested that persistent RVD might identify high-risk patients who may benefit from extending the period of long-term anticoagulation. 5 The present study did not demonstrate an association between persistent echocardiographic signs of RVD or PHT, 6 months after PE, and either all-cause mortality or VTE recurrence. Several possible reasons could account for the differences observed between our study and those previously reported. Grifoni et al. 5 performed the second echocardiography at hospital discharge, and Ribeiro et al. 4 only used the 1-month follow-up echocardiography in their survival analysis. In contrast, we evaluated the echocardiographic evolution after a longer interval of time, presuming that this would improve the correlation between this examination findings and the adverse events occurrence in the long-term. There are also differences in the populations studied that might explain the discrepancies in the results. The studies published by Ribeiro et al. and Grifoni et al. included patients with haemodynamic instability (thrombolytic agents were used in 41 and 14% of their cases, respectively, while none of our patients received this treatment). 4, 5 Of more importance, Grifoni et al. excluded from their study patients with prior documented PE and comorbidity (e.g. chronic obstructive pulmonary disease) that could justify the persistent RVD. 5 We did not exclude these cases from our study because we wanted to reflect a real-life clinical scenario. Therefore, it is possible that the right ventricular pressure overload in some of our patients could be influenced by previous comorbidity and, in such cases, echocardiographic abnormalities might have a different prognostic significance. By making an additional analysis that excluded cases with coexisting diseases that could account for the right ventricular pressure overload, we tried to correct this situation, but we did not find significant changes. Our study might be underpowered to detect a prognostic significance of echocardiography findings. The sample size is comparable to the study authored by Ribeiro et al., 4 and the follow-up period seems long enough to detect trends in adverse events. However, 18.9% of our patients were under long-term anticoagulation therapy and this might have reduced the incidence of VTE recurrence and, consequently, the statistical power of the study. Nevertheless, this raises the question of the real value of echocardiography to identify patients that might benefit from extended anticoagulation in clinical practice. We have recruited consecutive, haemodynamically stable PE patients in a medium-size hospital for a little more than 3 years, and after almost 3 years of follow-up, we have been unable to demonstrate an independent prognostic significance of echocardiography. This fact suggests that echocardiograpy does not add valuable information to the challenge of deciding when a particular patient must be kept indefinitely anticoagulated, beyond standard clinical criteria. However, because of the relatively small size of our sample, definitive recommendations regarding the value of follow-up echocardiographies cannot be made with our results. Another potential limitation of the study is the cut-off value of PASP used to diagnose PHT. Like other authors, 2 we decided to set the upper normal value at 40 mmHg. However, PASP is influenced by age and body weight, and many of our patients were elderly. Hence, false-positive diagnosis of PHT in some cases cannot be totally ruled out. Finally, due to the design of our study, reproducibility of the echocardiographic measurements could not be properly assessed.
In conclusion, echocardiographic signs of right ventricular pressure overload were not associated with an increased risk of death or recurrent VTE in our study. However, due to the limitations of design and size of our study, these results must be considered preliminary, and the real value of follow-up echocardiography to guide therapy in PE patients should be assessed in properly designed, randomized clinical trials.
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